Colorectal Cancer Drugs Market Size to hit US$ 19.96 billion by 2033 | Most Leading Companies - Bristol-Myers Squibb, AstraZeneca, Roche, Merck & Co., Pfizer

colorectal cancer drugs market size is projected to grow from US$ 12.60 billion in 2024 to US$ 19.96 billion by 2033, registering a CAGR of 5.2% during the forecast period.

DataM Intelligence has published a new research report on "Colorectal Cancer Drugs Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

In Canada, first-line chemotherapy costs an average of $8,992 per month, compared to $11,814 in the United States.

A recent study shows that adding Encorafenib and Cetuximab to FOLFOX chemotherapy improves survival in BRAF V600E-mutant metastatic colorectal cancer patients.

According to the American Cancer Society, colorectal cancer (CRC) is the third most diagnosed cancer and cause of cancer death in the U.S., with an estimated 154,000 new cases in 2025. It typically develops in the colon.

Rising colorectal cancer cases are driving advances in chemo, targeted, and immunotherapies. Drugs targeting VEGF, EGFR, KRAS, and HER2 are improving survival, while PD-1 inhibitors show promise in MSI-H patients. The FDA approved the NALIRIFOX combination in Feb 2024, emphasizing therapies that boost efficacy and overcome resistance.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/colorectal-cancer-drugs-market?kb

Key Report Highlights

North America dominates the Colorectal Cancer Drugs market with a 42.1% share in 2024, fueled by robust healthcare infrastructure, leading pharmaceutical companies like Pfizer and Bristol-Myers Squibb, and active FDA-backed clinical research.

Chemotherapy remains the top treatment type, holding a 57.6% share in 2024, supported by approved regimens and ongoing trials that reinforce its market leadership.

Intravenous administration leads the delivery segment and is expected to grow at a 4.5% CAGR, offering comprehensive cancer care, advanced technologies, and direct access to branded therapies.

Key Players:

Bristol-Myers Squibb, AstraZeneca, Roche, Merck & Co., Pfizer, Amgen, Bayer, Eli Lilly, Novartis, Ipsen, and Taiho Oncology

Key Development:

In February 2025, colorectal cancer-the third most common cancer in the U.S. showed a decline in incidence and mortality. The American Cancer Society reported a 1.2% annual decrease in death rates over the past decade, thanks to earlier detection and improved treatments, many pioneered at Memorial Sloan Kettering Cancer Center.

In March 2025, Apollo Hospitals Health City launched ColFit, a colorectal cancer screening program designed to promote early detection and prevention. The initiative aims to make screening a routine part of healthcare, enabling timely diagnosis, prevention, and improved treatment outcomes.

In December 2024, Pfizer received FDA approval for BRAFTOVI in combination with cetuximab and mFOLFOX6 to treat metastatic colorectal cancer patients with the BRAF V600E mutation, as confirmed by an FDA-approved test.

Growth Forecast Projected:

The Global Colorectal Cancer Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Colorectal Cancer Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=colorectal-cancer-drugs-market

Key Segments:

Chemotherapy leads CRC drugs market with 37.6% share

IV segment leads market, fastest growth at 4.5% CAGR

By Type: (Vascular endothelial growth factor inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, and BRAF or MEK Inhibitors)

By Therapy: (Immunotherapy, Targeted Therapy, and Chemotherapy)

By Distribution channels: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Colorectal Cancer Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Colorectal Cancer Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/colorectal-cancer-drugs-market?kb

FAQ's

Q1: How fast is the Colorectal Cancer Drugs Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 5.2% from 2025 to 2032

Q2: Which regions are dominating the Colorectal Cancer Drugs Market and which are fastest-growing?

A: Asia Pacific chemo market grows rapidly at 23.5%

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/colorectal-cancer-drugs-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.